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The systemic immune system has the ability to modulate multiple brain functions, including autonomic
responses, glial reactivity following neural injuries, and neuronal excitability. Immune stimuli also influence
microglia subpopulations originating from blood progenitors, and neuroprotective and reparative capacities
of blood-derived microglia were recently described in mouse models of spinal cord injury and brain disor-
ders. Furthermore, reparative roles for various immune subsets have been recognized, such as in inducing
myelin repair. Nonetheless, uncontrolled and excessive activation of immune responses can be detrimental.
The development of strategies to stimulate the systemic immune system safely to protect or repair brain
disorders remains a major challenge ahead, but important inroads have been made. We discuss here some
of themechanisms underlying the neuroprotective and reparative effects of the systemic immune system and
the most promising immunotherapies tested in mouse models of injuries and diseases, such as Alzheimer’s
disease, amyotrophic lateral sclerosis, and multiple sclerosis.Introduction
Inflammation is a general term for reactions occurring after most
kinds of tissue injuries or infections or immunologic stimulations
as a host defense against foreign or altered endogenous sub-
stances and to regain homeostasis or enable repair. The local
inflammatory reaction is characterized by an initial increase of
blood flow to the site of injury, enhanced vascular permeability,
and selective accumulation of different effector cells from the
peripheral blood to injured regions. These cells, mostly circu-
lating neutrophils and monocytes and local resident macro-
phages, together mount rapidly an inflammatory response that
is characterized, among other features, by cytokine production.
Their secretion into the bloodstream is a key step for triggering
the neuronal activity and subsequent neurophysiological
responses that take place during systemic and localized tissue
insults. Cytokines influence many neuroendocrine systems, the
most prominent of which is the activation of the hypothalamic-
pituitary adrenal (HPA) axis, resulting in the release of ACTH
and glucocorticoids. These steroids are the most powerful nega-
tive feedbacks on innate immune cells. Other autonomic func-
tions (e.g., fever, sickness behavior) are also dependent on bilat-
eral communications between the immune system and brain.
Circulating monocytes are also involved in the brain’s reaction
to systemic immune stimuli (D’Mello et al., 2009). Indeed,
D’Mello et al. recently found that peripheral TNFa signaling
stimulates monocyte chemoattractant protein (MCP)-1/CCL2
production in microglia, which drives the subsequent infiltration
of CCR2-expressing monocytes into the brain. These events
contribute significantly to the development of hepatic inflamma-
tion-associated sickness behavior (D’Mello et al., 2009).
Thus, immune cells can infiltrate the CNS in the presence of
systemic inflammation and modulate neural activities. Such aphenomenon was known to occur in brain diseases, the best
example being multiple sclerosis (MS), where immune dysfunc-
tion is robust and therapies are needed to reduce the prominent
entry of immune cells into the CNS. On the other hand, particu-
larly in conditions where systemic immune dysfunction is not as
widespread as that occurring in MS, such as Alzheimer’s disease
(AD) and amyotrophic lateral sclerosis (ALS), strategies have
been proposed to stimulate immune cells to improve neural
outcomes. While somewhat complicated, as inflammatory acti-
vation in these diseases can lead to both beneficial and detri-
mental effects (see Lucin and Wyss-Coray [2009] in this issue
of Neuron and Rivest [2009]), this review will focus specifically
on how one might take advantage of the systemic immune
system to treat brain diseases safely.
Immune Cells with a Systemic Origin
Despite having the same origin, circulating monocytes and
tissue macrophages, including microglia (Figure 1), encompass
a wide range of phenotypically and functionally distinct subpop-
ulations (Soulet and Rivest, 2008). Recently, a spectrum of acti-
vation has been elaborated for macrophages, consisting of two
main subgroups: inflammatory macrophages (M1) and alterna-
tively activated macrophages (M2a, -b, or -c). Each subgroup
is characterized by a distinct profile of gene expression, and
accordingly, each mediates and modulates different functions
(Nahrendorf et al., 2007). In this respect, M1 macrophages
express TNFa and iNOS and have important proteolytic activity,
while M2 macrophages possess important immunomodulatory
and tissue repair and remodeling properties (Martinez et al.,
2009). Similarly, two different populations of circulating mono-
cytes have been identified based on the expression pattern of
specific surface molecules (Auffray et al., 2009). In mice, theNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 55
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Microglia are the resident immune cells of the
brain, and they are constantly patrolling the cere-
bral microenvironment. As depicted by panel (A),
they are present in the entire central nervous
system (CNS), including the spinal cord. There are
regions that are more populated than others, and
the white matter generally contains less microglia
than the grey matter. They are highly ramified
cells, and their processes are very active and
plastic even during nonpathological conditions.
Although their exact origin still remains to be fully
established, both macrophages and microglial
cells derive from myeloid progenitors. There are
subpopulations of microglial cells, each of which
may have different origins, i.e., the primitive
macrophages from the yolk sac and those newly
differentiated from monocytes or their pro-
genitors. Concrete evidence demonstrating the
capacity of bone marrow stem cells (BMSCs) to
populate the CNS and differentiate into microglial
cells was obtained in chimeric mice transplanted
with bone marrow cells expressing green fluores-
cent protein (GFP). With the use of this model,
many researchers have found donor-derived cells
in the brain of host animals, and BMSCs indeed
have the ability to populate the CNS and differen-
tiate into functional parenchymal microglia as well
as perivascular microglia (C and E). It is important
to mention that the origin and role of microglia in
the adult brain still remain highly debated today.
(A and G) Resting microglia (green cells, immuno-
fluorescence using a primary antibody directed
against iba1; blue nuclei, DAPI).
(B, D, and F) Highly ramified microglia (red cell,
immunofluorescence using a primary antibody
directed against iba1).
(C and E) Bone-marrow-derived microglia from
chimeric mice transplanted with bone marrow stem
cells expressing green fluorescent protein (green
GFP cells). The confocal images of the microglia
subtypes were taken by Paul Pre´fontaine.relative expression levels of chemokine receptors CCR2 and
CX3CR1 (e.g., CCR2high/CX3CR1low; CCR2low/CX3CR1high)
define two subpopulations of monocytic cells, and interestingly,
each correlates with the presence of Gr1 and/or Ly-6C surface
antigen (Auffray et al., 2009). Therefore, CCR2+/Gr1+/Ly-6Chigh
defines inflammatory monocytes, while CX3CR1+/Gr1/Ly-
6Clow refers to blood-vessel-patrolling monocytes. However,
monocyte biology is becoming increasingly complex and may
be tissue dependent—an increasing number of cluster of differ-
entiation (CD) molecules are being validated to complement
other markers to ascertain exact subpopulations of monocytes
more specifically. As such, a third subset of the monocyte pop-
ulation (e.g., CD3CD19NK1.1Ter119SSCloCD11bhiCD62L+
Gr1int) may encompass the population of circulating precursors
of microglia (Soulet and Rivest, 2008). Although the differentia-
tion of monocytes into macrophages is not very well understood,
it appears that in a tissue under pathological conditions, newly
recruited CCR2+ monocytes give rise to M1-activated macro-
phages, while CX3CR1+ monocytes adopt a more M2-like profile
(Nahrendorf et al., 2007). The recruitment of each monocytic
population is time dependent, correlating with the different
phases of the tissue insult and repair. In vitro data corroborate
these observations, as proinflammatory ligands like LPS or
IFNg favor macrophage differentiation toward an M1 profile,56 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.while IL-4, IL-13, IL-10, and TGFb shift the development of
monocytes into a M2 phenotype. Much of these observations
are derived from studies on peripheral organs, and little is known
regarding whether such classification also exists for microglia
and how important different subsets are to brain functions,
injury, and diseases.
There is a massive infiltration of bone-marrow-derived micro-
glia (BMDM) during experimental models of stroke and most
mouse models of neuronal injury (Soulet and Rivest, 2008).
Although BBB disruption facilitates this recruitment, BMDM are
also found in models where the BBB is not compromised (e.g.,
in the hypoglossal nucleus after lesion of its innervating nerve).
Data from Schwartz and colleagues have shown that the spatial
organization of the infiltrating myeloid progenitor cells around the
lesion site has a direct impact on functional indices of recovery
following spinal cord injury; in another study, this group has
elegantly shown that infiltrating monocyte-derived cells mediate
a function essential for repair that cannot be provided by resident
microglia during spinal cord injury (Shechter et al., 2009). Spatial
organization and subpopulation of microglia/macrophages orig-
inating from blood precursors can therefore have a direct influ-
ence on the repair process occurring after injury of the CNS. It
is interesting to note that the activity of these innate immune cells
can be modulated by cells of the adaptive immune system.
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reactivity to injury and play a key cerebroprotective role in acute
experimental stroke (Liesz et al., 2009).
Systemic Immune Therapies in Alzheimer’s Disease
Many studies have provided evidence that microglial cells are
attracted to amyloid deposits both in human samples and in
rodent transgenic models that develop Alzheimer’s disease (AD)
(for a review, please see Simard et al. [2006]). We recently found
numerous BMDM closely associated with amyloid plaques, and
they serve to slow the progression of the disease by removing
amyloid beta (Ab) from the CNS (Simard et al., 2006). Upregulat-
ing TLR2 gene expression in bone marrow cells restores the
cognitive decline of the APP/PS1 mice in the context of TLR2
gene deficiency (Richard et al., 2008), and blocking TGF-b-
Smad2/3 innate immune signaling in bone-marrow-derived cells
improved AD-like pathology (Town et al., 2008). Brain paren-
chymal and cerebrovascular Ab deposits and Ab abundance
were markedly (up to 90%) attenuated in Tg2576-CD11c-DNR
mice (Town et al., 2008). This was associated with increased infil-
tration of Ab-containing peripheral macrophages around cere-
bral vessels and Ab plaques.
Consequently, stimulating the hematopoietic system may be
considered as a new therapeutic approach for treating AD
(Figure 2). In this regard, low macrophage colony-stimulating
Astrocyte
Neuron
Bone Marrow
Stem Cells
(BMSCs)
Viral transduction
Enhanced expression of:
+ TLRs (2, 4, 9) and CD14
+ Scavanger Receptors
+ Trophic factors
+ Amyloid-β degradating enzymes
+ Enzymes that activate pro-drugs
+ Chemoattractants (CCR2, ...)
Bone Marrow Transplantation
Blood
Blood Brain Barrier
Amyloid-β
Myeloid
Cells
Neurotrophins
Neurotrophins
Brain
Compounds that
activate or enhance
cell recruitment
Resident microglia
Bone Marrow-Derived Microglia
(BMDM)
Damaged Neuron
Immunization against amyloid-β
(active and passive)
Soluble
amyloid-β
Cytokines/
Mediators
Neuron
Plaque
degradation
Neurotrophins
(M-CSF, TLR ligands,
adjuvants, lifestyle, ...)
and innate immunity
Figure 2. Systemic Immune Approaches to
Clear Amyloid Beta in Alzheimer’s Disease
Activation of the systemic innate immune system
and bone marrow cells may be a powerful
approach to treat AD and eliminate Ab from the
CNS. This can be done by specific toll-like receptor
(TLR) ligands and other adjuvants, M-CSF, and
immunization against Ab. Other immunotherapies
that have been tested in mouse models of AD
include a T cell-based vaccination with glatiramer
acetate, a drug used in multiple sclerosis. Finally,
the genetic engineering of bone marrow stem cells
to upregulate genes encoding chemokine recep-
tors (e.g., CCR2), TLRs, CD14, Ab-degradating
enzymes, and neurotrophic factors may be a new
direction to improve recruitment and functionality
of bone-marrow-derived microglia/macrophages
(BMDMs) in the CNS and favor their polarization
toward neuroprotection. Such systemic immuno-
therapies may also be applied to other CNS
diseases, because toxic and extracellular proteins
are becoming a common feature of many brain
disorders.
factor (M-CSF) levels were found in
patients with presymptomatic AD or
mild cognitive impairment (MCI), which
together with low levels of other hemato-
poietic cytokines predicted the rapid evo-
lution of the disease toward a dementia
state 2–6 years later (Ray et al., 2007).
Systemic M-CSF administration is a
powerful treatment to stimulate bone-
marrow-derived microglia, degrade Ab,
and prevent or improve the cognitive
decline associated with Ab burden in
a mouse model of AD (Boissonneault et al., 2009). The mobiliza-
tion of precursor cells in the bone marrow together with the
effects of the cytokine on Ab degradation by microglia (Majum-
dar et al., 2007) are mechanisms underlying the great potential
of this systemic immune approach.
The recent papers by Ajami et al. (2007) and Mildner et al.
(2007) raised concerns regarding the ability of circulating
progenitors to enter and differentiate into functional microglia.
Their work suggests that such a phenomenon is a consequence
of the generation of chimeric mice using either BMSC transplan-
tation or irradiation. Technical details of chimeric models have
been discussed in a previous review (please see Soulet and Riv-
est [2008]). It is important to mention that beneficial effects of
BMDM in AD are not only reported in chimeric mice using the
irradiation technique, but also in nonirradiated mice. Moreover,
APP mice that have their hematopoietic system reconstituted
from WT mice always perform significantly better (e.g., less rapid
cognitive decline) than intact APP or chimeric APP mice trans-
planted with bone marrow stem cells taken from APP mice (M.
Filali and S.R., unpublished data). Overall, converging informa-
tion emphasizes that competent immune cells are highly benefi-
cial to clear toxic Ab; the challenge is to define the mechanisms
that will allow them to be more effectively recruited where they
are absolutely needed, and without incurring the harmful effects
of an overly stimulated immune system.Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 57
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against Ab1-42) in mouse models of AD were previously found
to remove Ab from the CNS, which ultimately improves the
cognitive decline associated with the amyloid cascade. These
data largely justified the first clinical trial with active immunization
in patients with mild to moderate cognitive impairment. Although
the clinical trial was stopped due to the meningo encephalitis
that developed in 6% of patients, the treatment seemed quite
effective to clear the senile plaques. Postmortem analysis of
a limited number of brains also revealed strong microglial reac-
tivity to Ab and infiltration of T cells. Other approaches to boost
immune functions have also been efficacious in animal models of
AD. Nasal vaccination with a synthetic copolymer used to treat
MS potently decreases senile plaques in a mouse model of AD
(Frenkel et al., 2005). Butovsky and colleagues have also shown
that a T cell-based vaccination with glatiramer acetate resulted
in decreased plaque formation and induction of neurogenesis
in APP mice (Butovsky et al., 2006). The vaccination apparently
exerted its effect by causing a phenotype switch of brain micro-
glia to dendritic-like (CD11c) cells producing insulin-like growth
factor 1.
These data suggest that activation of the systemic immune
system is a powerful approach to treat AD and eliminate Ab
from the CNS. While the phenotype switch of microglia may be
contributory, the recruitment of BMDM is likely another mecha-
nism. A better recruitment of these cells by systemic immune
stimuli may therefore be envisaged as being a novel clinical
tool to eliminate toxic senile plaques in the brain of AD patients.
It is also possible that immunotherapy modifies resident micro-
glia to be better phagocytes, which could be another mechanism
to target the amyloid cascade (Figure 2).
One can therefore be surprised by the recent clinical trial using
passive immunization with humanized monoclonal anti-Ab anti-
body (bapineuzumab), presented by Elan/Wyeth, of an overall
negative result balanced against a positive effect on a subgroup
of patients who do not carry the AD risk allele ApoE4. That this
phase 2 trial showed no major cognitive improvement in AD
patients raises the question as to whether immunization with
Ab is the direction to take. Nonetheless, it is still premature to
conclude that immunization against Ab may not be effective,
because this is likely to depend on the preparation, antigen
target, adjuvant, and subgroup of patients. We speculate that
vaccines that stimulate the hematopoietic system and microglia
precursors to produce phagocytes that remove Ab will have
better success to treat AD patients.
In Other Brain Diseases
Infiltration of bone-marrow-derived microglia has been
described in other mouse models of brain diseases, including
Parkinson’s disease, amyotrophic lateral sclerosis (ALS), chronic
pain, prion disease, and the mouse model of MS—experimental
allergic encephalomyelitis (EAE). These cells were also found in
the CNS of MS and ALS patients. A marked clinical improvement
has recently been reported in MS patients transplanted with
autologous hematopoietic stem cells—62% of patients were
disease free after 3 years (Burt et al., 2009). By contrast, unmod-
ified hematopoietic stem cells failed to have any benefit for
sporadic ALS patients (Appel et al., 2008). In mice, transplanta-58 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.tion of bone marrow cells from wild-type mice did not affect
disease progression in either the G37R-SOD1 or G93A–SOD1
mouse model of ALS (Kang and Rivest, 2007). However, trans-
plantation of MyD88-deficient (MyD88 pathway mediates micro-
glial activation and infiltration) bone marrow cells dramatically
changed the disease onset and progression, but only in mice
that express human mutant G37R (Kang and Rivest, 2007).
G37R-SOD1 mice that received MyD88-competent bone-
marrow-derived microglia developed the disease later, survived
longer, and had less neurodegeneration than those that were
transplanted with MyD88-deficient bone marrow cells (Kang
and Rivest, 2007). The results from the chimeric mice suggest
that bone-marrow-derived microglia act as a natural defense
mechanism against secreted mutant SOD1. Vaccination against
SOD1 is also protective in mouse models of ALS (Urushitani
et al., 2007).
We have also found beneficial effects of MyD88-competent
BMDM in mouse models of AD (K. Richard and S.R., unpub-
lished data). Since toxic proteins are produced in many dis-
eases, including those associated with abnormal prions, it is
tempting to propose a similar beneficial role for innate immune
cells in reducing neuropathology associated with secreted toxic
molecules.
Harnessing the Benefits of Inflammation for Repair
The above discussion emphasizes the benefits of BMDM in
removing toxic materials to confer protection to neurons. Other
immune subsets, such as T lymphocytes, also confer neuropro-
tection and, in some context, repair. Through a process referred
to as ‘‘protective autoimmunity,’’ autoreactive T cells protected
local axons and neurons from degenerating after a traumatic
injury to the spinal cord (Schwartz et al., 1999), even while other
areas of the CNS were subjected to undesirable consequences
of autoreactive immune cells. In normal hippocampal neurogen-
esis, immune activity is required since neurogenesis is impaired
in T cell-deficient mice; the restoration of T cell activity improved
the number of adult neurons and spatial learning (Ziv and
Schwartz, 2008).
Akin to the repair function of inflammation in other tissues,
neuroinflammation has also been observed to confer regenera-
tion of the nervous system. Remyelination, which is a repair
process that occurs quite robustly in the mammalian CNS, is
impaired in demyelinated mice that are devoid of T cells, macro-
phages, particular cytokines such as TNF-a and IL-1b, or leuko-
cyte-derived proteases such as the matrix metalloproteinases
(MMPs) (Yong, 2005). Axonal regeneration has also been
reported to be facilitated by immune subsets, and a macro-
phage-derived factor that promotes axonal regeneration after
optic nerve crush injury has been identified to be oncomodulin
(Yin et al., 2006). The mechanisms by which immune cell subsets
confer neuroprotection or recovery remain speculative, but
leukocytes are known to express a range of neurotrophic factors,
including the neurotrophin class of survival and regenerative
factors for neural cells during development and in adulthood. It
is pertinent that even in the classic inflammatory disease of the
CNS, MS, where extensive and dysfunctional immune reactivity
contribute to the pathology, many of the immune cells that accu-
mulate in the CNS express neurotrophic factors. Other beneficial
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clearance of toxic molecules as aforementioned and the removal
of cellular debris as a prelude to repair (Figure 3). Moreover, bone
marrow stem cells may differentiate to repopulate neural cells
even though evidence is lacking for this phenomenon. Further-
more, leukocytes produce MMPs that can remove nonpermis-
sive extracellular matrix proteins such as the NG2 proteoglycan
(Yong, 2005) to result in a milieu that is more conducive for repair
processes.
Given the beneficial aspects of inflammatory cells, one is
faced with the dilemma of using immunomodulators that down-
regulate systemic immunity even in inflammatory disorders of
the CNS such as MS. We would posit that it is appropriate to
use immunomodulators when the CNS is besotted by extensive
numbers and activity of immune cells, since it is necessary to
reduce neuroinflammation to a homeostatic level, even if one
loses out on the beneficial aspects of immune cells. The chal-
lenge is when to stop the use of potent anti-inflammatory agents,
since their long-term use may chronically reduce beneficial
immune cells and thus compromise CNS integrity. Indeed, there
are several examples in the literature of corticosteroid use that
has resulted in impaired neuroprotection or remyelination in
animal models.
Is it possible to stimulate inflammatory processes safely for
repair, particularly in inflammatory diseases such as MS? We
believe that this is possible, given the improved understanding
Table 1. Mechanisms of the Benefits of Inflammatory Cells in the
CNS
 Clearance of cellular debris as a prelude to repair
 Detoxification and clearance of toxic molecules, including Ab,
SOD1, and prions
 Provision of a spectrum of neurotrophic factors
 Removal of nonpermissive proteoglycans that hinder axonal
regeneration or remyelination
 Bone-marrow-derived stem cells may contribute to repopulation of
neural cellsof less proinflammatory immune cell subsets such as M2 mono-
cytes and CD4+ T helper 2 cells that produce anti-inflammatory
cytokines while producing neurotrophic factors that is a feature
of all leukocyte subsets. Indeed, the MS medication glatiramer
acetate generates both subsets, and we were able to demon-
strate that its administration to mice with demyelination of the
spinal cord resulted in increased levels of neurotrophic factors
in the injured spinal cord correspondent with a greater extent
of remyelination (Skihar et al., 2009).
Concluding Remarks
It is clear that a better understanding of the role of subpopula-
tions of microglia/macrophages and lymphocytes in the brain
is required before we can safely develop new treatments to stim-
ulate their infiltration for preventing neuronal damage, improving
repair, and eliminating toxic proteins. Moreover, we have yet to
unravel the mechanisms by which these cells can be recruited
in a more efficient manner without having side effects associated
with their inflammatory characteristics. This remains a major
challenge ahead due to possible drawbacks of immune cells
and molecules on neuronal elements. It is also crucial to unravel
how microglia/macrophages interact with specific Ab isoforms
and other toxic proteins involved in chronic brain diseases. We
will then have more specific targets to modify and ultimately
prevent neuronal damages associated with accumulation of
these molecules in the extracellular milieu. The field of harness-
ing beneficial inflammation is new, but it promises to hold great
potential to confer several beneficial outcomes for the injured
CNS across a variety of disorders, including those classically
associated with inflammation, such as MS. One is hard-pressed
to think of better strategies to protect and regenerate the CNS
than to use an endogenous system that has withstood evolu-
tionary pressures: inflammation.
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